ADiTx Therapeutics Inc.
| NASDAQ: ADTX | Healthcare / Biotechnology / USA |
| 18.09 | +0.1000 | +0.56% | Vol 235.73K | 1Y Perf 484.09% |
| Sep 22nd, 2023 15:59 DELAYED |
| BID | 17.40 | ASK | 18.91 | ||
| Open | 17.40 | Previous Close | 17.99 | ||
| Pre-Market | - | After-Market | 17.99 | ||
| - - | -0.10 -0.55% |
| Target Price | 4.00 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | -77.89 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 46.46 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.27 | Earnings Rating | — | |
| Market Cap | 3.44M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.07 | Standard Deviation | 0.48 | |
| Beta | 0.64 |
Today's Price Range 15.6122.50 | 52W Range 7.34178.80 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.33% | ||
| 1 Month | 71.31% | ||
| 3 Months | 3 518.72% | ||
| 6 Months | 1 938.54% | ||
| 1 Year | 484.09% | ||
| 3 Years | 842.19% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -366.40 | |||
ROE last 12 Months | -339.11 | |||
ROA (5Y Avg) | -82.32 | |||
ROA last 12 Months | -224.52 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -242.40 | |||
Return on invested Capital Q | -49.04 | |||
Return on invested Capital Y | -320.25 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.44 | ||||
| 7.41 | ||||
| - | ||||
| -0.40 | ||||
| -25.29 | ||||
| 0.45 | ||||
| 2.96 | ||||
| -65 953.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.40 | ||||
| 2.90 | ||||
| 0.14 | ||||
| 0.28 | ||||
| -18.00 | ||||
| Leverage Ratio | 2.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 20.90 | ||||
| -4 832.10 | ||||
| -4 772.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 748.12K | ||||
| 0.17 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -115.60 | -36.80 | 68.17 |
| Q01 2023 | -73.20 | -52.40 | 28.42 |
| Q03 2022 | -100.00 | -210.80 | -110.80 |
| Q02 2022 | 220.00 | -260.00 | -218.18 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -5.99 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 235.73K |
| Shares Outstanding | 190 |
| Shares Float | 186.27K |
| Trades Count | 2.44K |
| Dollar Volume | 4.19M |
| Avg. Volume | 286.01K |
| Avg. Weekly Volume | 92.75K |
| Avg. Monthly Volume | 339.59K |
| Avg. Quarterly Volume | 425.69K |
ADiTx Therapeutics Inc. (NASDAQ: ADTX) stock closed at 18.09 per share at the end of the most recent trading day (a 0.56% change compared to the prior day closing price) with a volume of 235.73K shares and market capitalization of 3.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. ADiTx Therapeutics Inc. CEO is Amro A. Albanna.
The one-year performance of ADiTx Therapeutics Inc. stock is 484.09%, while year-to-date (YTD) performance is 1466.78%. ADTX stock has a five-year performance of %. Its 52-week range is between 7.34 and 178.8, which gives ADTX stock a 52-week price range ratio of 6.27%
ADiTx Therapeutics Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 0.44, a price-to-sale (PS) ratio of 7.41, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -224.52%, a ROC of -242.40% and a ROE of -339.11%. The company’s profit margin is -%, its EBITDA margin is -4 772.70%, and its revenue ttm is $748.12 Thousand , which makes it $0.17 revenue per share.
Of the last four earnings reports from ADiTx Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-5.99 for the next earnings report. ADiTx Therapeutics Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for ADiTx Therapeutics Inc. is Moderate Buy (2), with a target price of $4, which is -77.89% compared to the current price. The earnings rating for ADiTx Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ADiTx Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ADiTx Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 61.40, ATR14 : 6.17, CCI20 : -35.01, Chaikin Money Flow : -0.15, MACD : 1.98, Money Flow Index : 16.75, ROC : -45.10, RSI : 49.99, STOCH (14,3) : 8.81, STOCH RSI : 0.06, UO : 32.93, Williams %R : -91.19), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ADiTx Therapeutics Inc. in the last 12-months were:
ADiTx Therapeutics Inc.
ADiTx Therapeutics Inc is a pre-clinical stage, life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
CEO: Amro A. Albanna
Telephone: +1 909 488-0844
Address: 11161 Anderson Street, Loma Linda 92354, CA, US
Number of employees: 43
